FDA Approval of Ceritinib for ALK-Mutated Lung Cancer Treatment – 2014
Reading tools
Approved by the FDA on 29 April 2014, Zykadia is used to treat late-stage non-small cell lung cancers.
ALK (anaplastic lymphoma kinase), which carries a cancer-causing risk, is suppressed by Zykadia, which has high affinity for it. The 4. drug to receive FDA approval in lung cancer, Zykadia causes the general side effects associated with most cancer drugs.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.